{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:19:05Z","timestamp":1773274745881,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,10,20]],"date-time":"2004-10-20T00:00:00Z","timestamp":1098230400000},"content-version":"vor","delay-in-days":2119,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>Although antithyroid drugs (ATD) are widely used in the treatment of Graves' disease, management protocols, especially treatment duration, remain a subject of debate. The rate of relapse after short\u2010term regimens of less than 6 months with ATD at decreasing doses is higher than after longer treatments from 12 to 24 months. As no prospective study has provided data on even longer protocols exceeding 2 years, we conducted a prospective trial to determine potential benefits of a 42\u2010month treatment compared with an 18\u2010month treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>DESIGN, PATIENTS AND MEASUREMENTS<\/jats:title><jats:p>The aim of this prospective randomized trial was to compare relapse rates achieved two years after treatment withdrawal in patients who received carbimazole at decreasing doses for 18 months (<jats:italic>n<\/jats:italic>\u2003=\u200362) <jats:italic>vs <\/jats:italic>42 months (<jats:italic>n<\/jats:italic>\u2003=\u200372). In addition to clinical relapse rate, the percentage of patients who normalized antithyroperoxidase (TPO) antibody and anti\u2010TSH receptor stimulating antibody (TSAb) levels and early iodine uptake at the end of treatment were assessed as outcome criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The relapse rate two years after discontinuation of treatment did not differ significantly in patients treated for 18 months from those treated for 42 months (36% <jats:italic>vs <\/jats:italic>29%, NS). At the end of treatment, there was no significant difference between the two groups in the percentage of anti\u2010TPO positive patients (53% <jats:italic>vs <\/jats:italic>46%, NS) or early iodine uptake (27% <jats:italic>vs <\/jats:italic>21%, NS). Although the percentage of patients with TSAb was significantly lower in the 42\u2010month treatment group (18% <jats:italic>vs <\/jats:italic>42%, <jats:italic>P<\/jats:italic>\u2003=\u20030.004) at treatment withdrawal, the percentage of TSAb\u2010positive patients did not significantly decrease between 18 and 42 months in this group (27% <jats:italic>vs <\/jats:italic>18%, NS).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Treatment duration greater than 18 months did not improve remission rate determined 2 years after treatment withdrawal or immunological variables or early iodine uptake measured at the time of discontinuation of treatment. These findings would indicate that, when a defined duration treatment is planned, prolonging treatment beyond 18 months does not provide any additional benefit.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2265.1999.00629.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T10:34:32Z","timestamp":1027679672000},"page":"127-132","source":"Crossref","is-referenced-by-count":87,"title":["Antithyroid drugs and Graves' disease \u2014 prospective randomized assessment of long\u2010term treatment"],"prefix":"10.1111","volume":"50","author":[{"given":"D.","family":"Maugendre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gatel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Campion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Massart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Guilhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Lorcy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lescouarch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Y.","family":"Herry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Allannic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(69)90133-4"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-30-4-540"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-3-675"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb03406.x"},{"key":"e_1_2_6_6_2","first-page":"221","article-title":"Early remission in thyrotoxicosis produced by short course of treatment","volume":"100","author":"Bing R.F.","year":"1982","journal-title":"Acta Endocrinologica (Copenh)"},{"key":"e_1_2_6_7_2","unstructured":"Bornet H. Madec A.M. Rodien P. Latter R. Haond P. Allannic H.&Orgiazzi J.(1990) Evaluation of anti\u2010thyroperoxidase antibodies determination in various clinical situations. In:Thyroperoxydase and Thyroid Autoimmunity Vol. 207 (eds. P. Carayon & J. Ruf) pp.315\u2013320. Colloque INSERM\/ John Libbey Eurotext Paris."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-55-6-1138"},{"key":"e_1_2_6_9_2","first-page":"447","article-title":"Evaluation of serum basal thyrotropin levels and thyrotropin receptor antibody activities as pronostic markers for discontinuation of antithyroid drugs in patients with Graves' disease","volume":"120","author":"Cho B.Y.","year":"1989","journal-title":"Clinical Endocrinology"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/08916939109007649"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-6-891"},{"key":"e_1_2_6_12_2","first-page":"557","article-title":"Am\u00e9lioration du pronostic de la maladie de Basedow par l'utilisation de fortes doses de Carbimazole","volume":"12","author":"Duprey J.","year":"1983","journal-title":"Presse M\u00e9dicale"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6670.359"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.1.98"},{"key":"e_1_2_6_15_2","first-page":"3","article-title":"The management of hyperthyroidism due to Graves' disease in Europe in 1986: results of international survey","volume":"285","author":"Glinoer D.","year":"1987","journal-title":"Acta Endocrinologica (Copenh)"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197707282970401"},{"key":"e_1_2_6_17_2","first-page":"328","article-title":"Retrospective revaluation of the significance of thyroid microsomal antibody in the treatment of Graves'disease","volume":"114","author":"Hamada N.","year":"1987","journal-title":"Acta Endocrinologica (Copenh)"},{"key":"e_1_2_6_18_2","first-page":"199","article-title":"Int\u00e9r\u00eat pronostique de la mesure de la captation thyro\u0131amp;;uml;dienne dans le traitement m\u00e9dical de l'hyperthyo\u0131amp;;uml;die. R\u00e9sultats \u00e0 5 ans","volume":"16","author":"Hartemann P.","year":"1975","journal-title":"Revue Fran\u00e7aise D'endocrinologie Clinique"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104043241403"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-26-8-803"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","unstructured":"Hershman J.M.(1995). Editorial: Does thyroxine therapy prevent recurrence of Graves hyperthyroidism.Journal of Clinical Endocrinology and Metabolism 80 1479\u20131480.","DOI":"10.1210\/jcem.80.5.7744988"},{"key":"e_1_2_6_22_2","first-page":"39","article-title":"Goitre size and outcome of medical treatment of Graves' disease","volume":"111","author":"Laurberg P.","year":"1986","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_6_23_2","first-page":"95","article-title":"Traitement de l'hyperthyro\u0131amp;;uml;die par antithyro\u0131amp;;uml;diens de synth\u00e8se: valeur pronostique de la captation thyro\u0131amp;;uml;dienne (recul de 4 ans)","volume":"4","author":"Lecl\u00e8re J.","year":"1980","journal-title":"Annales D'endocrinologie"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-64-6-1241"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.8.2410"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1984.tb03466.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/clinchem\/32.7.1332","article-title":"Assay for thyrotropin\u2010receptor binding and thyroid stimulating antibodies in sera from patients with Graves' disease","volume":"32","author":"Massart C.","year":"1986","journal-title":"Clinical Chemistry"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/clinchem\/37.10.1777","article-title":"Comparison of thyroperoxidase and microsomal antibodies assay in sera from patients with Graves' disease","volume":"37","author":"Massart C.","year":"1992","journal-title":"Clinical Chemistry"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.284.6331.1750"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601253340403"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-60-6-1237"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.00800.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-58-2-332"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.6.1516"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-57-3-563"},{"key":"e_1_2_6_36_2","unstructured":"Rubello P.(1990) Pronostic value of anti\u2010TSH receptor antibodies assay in 85 patients treated for Graves' disease. In:The Thyroid Gland Environment and Autoimmunity (eds. H.A. Drexhage J.J.M. De Vigdler & W.M. Wiersinger) pp.263\u2013268. Elsevier Science Publishers BV Amsterdam."},{"key":"e_1_2_6_37_2","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/clinchem\/34.11.2231","article-title":"Nouvel routine assay for thyroperoxidase","volume":"34","author":"Ruf J.","year":"1988","journal-title":"Clinical Chemistry"},{"key":"e_1_2_6_38_2","first-page":"689","article-title":"Prospective multicenter study on the prediction of relapse after antithyroid Graves' disease","volume":"120","author":"Schleusener H.","year":"1989","journal-title":"Acta Endocrinologica (Copenh)."},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-68-6-1097"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-92-4-488"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1984.tb03456.x"},{"key":"e_1_2_6_42_2","first-page":"337","article-title":"Treatment of Graves'disease with the block\u2010replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse","volume":"87","author":"Weetman A.P.","year":"1994","journal-title":"Quarterly Journal of Medicine"},{"key":"e_1_2_6_43_2","first-page":"666","article-title":"The pronostic value of TSH receptor binding thyroid stimulating antibodies following antithyroid drug treatment of Graves' disease","volume":"121","author":"Wilson R.","year":"1989","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1983.tb00021.x"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1999.00629.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1999.00629.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.1999.00629.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T14:52:11Z","timestamp":1698504731000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.1999.00629.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1046\/j.1365-2265.1999.00629.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.1999.00629.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}